Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review
Haiyang Guo,Jun Zhang,Chao Qin,Hang Yan,Xinyue Luo,Haining Zhou
DOI: https://doi.org/10.1097/md.0000000000036861
IF: 1.6
2024-01-20
Medicine
Abstract:Lung cancer is the most common cancer globally and the leading cause of cancer-related deaths. [ 1 ] The most frequent pathological form of lung cancer is non-small cell lung cancer (NSCLC), which accounts for 85 percent of all lung cancer cases. [ 1 , 2 ] In most cases, lung cancer is treated with radiation, chemotherapy, surgical intervention, and immunotherapy. [ 1 , 2 ] Prior to immunotherapy, platinum-based chemotherapy is the standard treatment for mNSCLC patients. [ 3 ] Platinum-based chemotherapy is the cornerstone of treatment for patients with metastatic NSCLC (mNSCLC). [ 4 ] Although both standard chemotherapy and immunotherapy can prolong patient survival, immunotherapy in any line of treatment, particularly first-line therapy, promotes survival in patients with mNSCLC. [ 5 , 6 ] mNSCLC has recently been revolutionized by the incorporation of immunotherapy into the standard platinum-based chemotherapy. In NSCLC, immune checkpoint inhibitors (ICIs), a common type of immunotherapy, also known as biologic treatment, have shown clinical success. [ 7 ] The 2 main classes of ICIs are programmed death-ligand 1 (PD-(L)1) Inhibitor and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors. T lymphocytes quickly express programmed death-1 (PD-1) on their surfaces after activation, and their ligands are PD-L1 and PD-L2. [ 8 ] Binding of T cell surface PD-1 to tumor cell PD-L1 inhibits T cell-associated kinases and prevents cytotoxic T cell responses to tumors. The binding of PD-L1 to its receptor PD-1 on activated T cells reduces antitumor immunity by lowering T cell proliferation, cytokine production, and cytotoxic capacity. [ 9 ] In many types of cancer, CTLA-4 is an important negative regulator of T cell responses, eventually resulting in T cell fatigue and T cell malfunction. [ 10 , 11 ] CTLA-4 inhibition can boost antitumor T-cell immunity. [ 12 ] ICIs targeting CTLA4, PD-1, and its ligand PD-L1 have shown considerable promise in clinical trials for a range of malignancies, including metastatic melanoma, NSCLC, and renal cell carcinoma (RCC). Currently, immunotherapy, either alone or in conjunction with chemotherapy, is the standard first-line treatment for advanced NSCLC. [ 13 ] This review focused on NSCLC. Excluding mNSCLC, which is positive for driver genes, practically all driver-negative mNSCLC patients are now treated with ICIs, which considerably improves patient survival. [ 14 ] Here, we discuss the current state of first-line immunotherapy in mNSCLC as well as the challenges and expectations for the first-line treatment of mNSCLC in the future (Fig. 1).
medicine, general & internal